K. Fei

发表

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

P. Lipsky, G. Tsokos, K. Lo, 2020 .

Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO‐MORE study

V. Shobha, B. Dharmanand, Siddharth K Das, 2016, International journal of rheumatic diseases.

Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease

C. Lines, B. Chaitman, S. Aurora, 2012, Headache.

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.

C. Bao, Chenglong Han, F. Huang, 2014, Rheumatology.

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

Tsutomu Takeuchi, Ravi Rao, P. Tak, 2017, Annals of the rheumatic diseases.

Randomized, controlled trial of telcagepant for the acute treatment of migraine

C. Lines, K. Connor, R. Shapiro, 2009, Neurology.

Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study

B. Hsu, C. Thorne, T. Takeuchi, 2018, RMD Open.

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

K. Kalunian, T. Dörner, K. Lo, 2022, Annals of the Rheumatic Diseases.

AB0341 Favorable Effects of Sirukumab Treatment on Physical Function and Reductions in Morning Stiffness in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Disease-Modifying Anti-Rheumatic Drugs

B. Hsu, C. Han, C. Thorne, 2016 .

SAT0145 Efficacy and Safety of Sirukumab in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of A Randomized, Double-Blind, Placebo-Controlled Study

B. Hsu, C. Thorne, T. Takeuchi, 2016 .

SAT0167 Health-Related Physical and Emotional Well-Being and Fatigue Improve Significantly with Sirukumab Treatment: Results of A Phase 3 Study in Patients with Active Rheumatoid Arthritis Refractory To Conventional Disease-Modifying Anti-Rheumatic Drugs

B. Hsu, C. Han, C. Thorne, 2016 .

Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study

P. Lipsky, G. Tsokos, K. Lo, 2021, The Journal of Rheumatology.

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double‐Blind, Placebo‐Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus

P. Lipsky, G. Tsokos, K. Lo, 2019, Arthritis & rheumatology.